港股市場個股詳情

01099 國藥控股

添加自選

21.500
+0.750+3.61%

休市中 05/10 16:08 (北京)

670.94億總市值6.85市盈率TTM

國藥控股股票討論區

登錄發表評論

Moomoo AI

03/27 06:49

Analysts have downgraded their earnings per share estimates for Sinopharm Group, indicating a decline in sentiment. They also suggest that Sinopharm may underperform compared to the wider industry, but the consensus price target remains steady.

Earnings Update: Sinopharm Group Co. Ltd. (HKG:1099) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

让子弹飞（SG)

03/13 10:56

$國藥控股(01099.HK)$ *大和首予國藥(01099.HK)「買入」評級目標價25元

Moomoo AI

03/13 07:10

Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.

Sinopharm Group (HKG:1099) Will Be Hoping To Turn Its Returns On Capital Around

Spinee

01/17 16:21

HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off

$恒生指數(800000.HK)$ plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion.
Pharmaceuticals were sold off. $榮昌生物(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$三葉草生物-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亞生物(01873.HK)$ ...

Moomoo AI

01/16 06:51

Sinopharm Group's low P/E ratio is due to investors' limited growth expectations, leading to a reduced stock price. The poor earnings outlook from analysts also contributes to its low P/E. These conditions may continue to hinder the share price.

Investors Don't See Light At End Of Sinopharm Group Co. Ltd.'s (HKG:1099) Tunnel

Moomoo AI

2023/12/31 08:32

Sinopharm Group is currently undervalued and it might be a good time to accumulate more holdings in the stock. The positive outlook on the horizon of the company's future seems not to be fully factored into the current share price.

Why Sinopharm Group Co. Ltd. (HKG:1099) Could Be Worth Watching

Moomoo AI

2023/11/01 07:29

The declining trend in Sinopharm Group's ROCE and the stock's 42% fall in the last five years doesn't inspire investor confidence. The article doesn't consider Sinopharm Group as a potential multi-bagger based on the present analysis.

Sinopharm Group (HKG:1099) May Have Issues Allocating Its Capital

Steven000

2023/04/27 17:21

專欄港股收評：恒指漲0.42% ，內險股大爆發，中國平安績後漲超9%

$恒生指數(800000.HK)$ 、 $國企指數(800100.HK)$ 上漲0.42%、0.32%， $恒生科技指數(800700.HK)$ 表現較弱，下跌0.26%。
今日，港股午後現快速拉升行情，恒指、國指午後維持漲勢，收盤分別上漲0.42%和0.32%，恒生科技指數表現較弱下跌0.26%。南下資金全日淨流入14.97億港元，大市成交額爲970億港元。
盤面上，大型科技股漲跌不一， $快手-W(01024.HK)$ 漲超1%， $小米集團-W(01810.HK)$ 、 $美團-W(03690.HK)$ 小幅上漲， $阿里巴巴-SW(09988.HK)$ 、 $百度集團-SW(09888.HK)$ 跌近2%；險企首季一季報業績大增，內險股全天強勢領漲，中國平安績後勁升9%表現十分亮眼；大型基建股拉升明顯，中字頭股表現較佳，軍工股、黃金股、特斯拉概念股、香港本地銀行股多數走俏。另一方面，半導體股、建材水泥股延續跌勢...

已翻譯